Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC Clinical Trial

Official title:
A Phase I/II Study to Assess the Safety,Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Patients With Locally Advanced or Metastatic T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

Status Recruiting

Clinical Trial Summary

ASK120067 Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor which can efficient suppress the EGFR T790M drug-resistant mutation tumor cell in Xenograft mouse model. This study aims at local advanced or metastatic non-small cell lung cancer patients with T790M drug-resistant mutation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Locally Advanced or Metastatic NSCLC

Clinical Trial Details

NCT number	NCT03502850
Study type	Interventional
Source	Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Contact	Tingting Song
Phone	025-85100150
Email	songtingting@ask-pharm.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	November 30, 2017
Completion date	August 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03037086` - Asia PDL1 Study Among NSCLC Patients	N/A
Recruiting	`NCT05662670` - A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03274479` - PBF-1129 in Patients With NSCLC	Phase 1
Not yet recruiting	`NCT05990127` - A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT03969823` - Whole Genomic Landscape of Advanced EGFR-mutant NSCLC	N/A
Completed	`NCT04207775` - Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
Completed	`NCT05631678` - Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole	Phase 1
Recruiting	`NCT04143607` - ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC	Phase 3
Completed	`NCT03414814` - Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation	Phase 2
Completed	`NCT04360915` - Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects	Phase 1